Company profile: Mirna Therapeutics
1.1 - Company Overview
Company description
- Provider of microRNA-directed oncology therapies as a biopharmaceutical company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mirna Therapeutics
Clinical Laserthermia Systems
HQ: Sweden
Website
- Description: Provider of the TRANBERG® Thermal Therapy System and disposable materials for image-guided, minimally invasive laser ablation and heat-induced immunotherapy (imILT®), offering focal therapy for localized prostate cancer, careful therapy of brain lesions/epileptogenic foci, immune-stimulating laser ablation, and the Thermoguide Workstation for real-time treatment monitoring and control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clinical Laserthermia Systems company profile →
ValiRx
HQ: United Kingdom
Website
- Description: Provider of oncology therapeutics and diagnostics R&D in the United Kingdom, including VAL 101 that acts to shut down the Bcl-2 gene (a proto-oncogene) and human papilloma virus diagnostic products based on the Nucleosomics platform. Offers an evaluation pipeline for cancer projects, Inaphaea BioLabs cell-based assays in oncology and women’s health, and a partnering strategy to optimize development, minimize risk, and advance early-stage programs toward clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ValiRx company profile →
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
BioVex
HQ: United Kingdom
Website
- Description: Provider of biological treatments for cancer and infectious diseases, focused on development and commercialization. Its cancer program includes OncoVEXGM-CSF, an oncolytic vaccine/cancer-destroying virus that replicates and spreads within solid tumors, causing tumor destruction, and it advances biological treatments for the prevention of infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVex company profile →
MirImmune Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on new and improved cancer immunotherapies, combining immune checkpoint inhibition and cell-based immunotherapies, aiming to achieve long-term survival of cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MirImmune Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mirna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mirna Therapeutics
2.2 - Growth funds investing in similar companies to Mirna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mirna Therapeutics
4.2 - Public trading comparable groups for Mirna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →